 These are deals in which a brand-name drug firm pays its potential generic drug rival to prevent price competition in the market.As Leibowitz explained, the practice results not only in windfalls for both companies—sometimes of more than a billion dollars—but also in higher drug prices for consumers.Leibowitz has published articles on this issue and advocates bringing cases against firms that engage in these practices.